Agenus Inc $ 3.90 0.46 (13.37%)
Volume:
4,787,296
Avg Vol (1m):
2,206,014
Market Cap $:
741.58 Mil
Enterprise Value $:
656.35 Mil
P/E (TTM):
0.00
P/B:
0.00
Current and historical daily P/E ratio for Agenus Inc () from 2000 to Jan 25 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Agenus stock (AGEN) PE ratio as of Jan 25 2021 is 0.
More Details
Agenus PE Ratio (TTM) Chart
EMBED
Agenus PE Ratio (TTM) Historical Data
View and export this data going back to 2000. Start your Free Trial
Total 1259
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Agenus PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2021-01-26 | 0.0 | 2020-11-24 | 0.0 |
| 2021-01-25 | 0.0 | 2020-11-23 | 0.0 |
| 2021-01-22 | 0.0 | 2020-11-20 | 0.0 |
| 2021-01-21 | 0.0 | 2020-11-19 | 0.0 |
| 2021-01-20 | 0.0 | 2020-11-18 | 0.0 |
| 2021-01-19 | 0.0 | 2020-11-17 | 0.0 |
| 2021-01-18 | 0.0 | 2020-11-16 | 0.0 |
| 2021-01-15 | 0.0 | 2020-11-13 | 0.0 |
| 2021-01-14 | 0.0 | 2020-11-12 | 0.0 |
| 2021-01-13 | 0.0 | 2020-11-11 | 0.0 |
| 2021-01-12 | 0.0 | 2020-11-10 | 0.0 |
| 2021-01-11 | 0.0 | 2020-11-09 | 0.0 |
| 2021-01-08 | 0.0 | 2020-11-06 | 0.0 |
| 2021-01-07 | 0.0 | 2020-11-05 | 0.0 |
| 2021-01-06 | 0.0 | 2020-11-04 | 0.0 |
| 2021-01-05 | 0.0 | 2020-11-03 | 0.0 |
| 2021-01-04 | 0.0 | 2020-11-02 | 0.0 |
| 2021-01-01 | 0.0 | 2020-10-30 | 0.0 |
| 2020-12-31 | 0.0 | 2020-10-29 | 0.0 |
| 2020-12-30 | 0.0 | 2020-10-28 | 0.0 |
| 2020-12-29 | 0.0 | 2020-10-27 | 0.0 |
| 2020-12-28 | 0.0 | 2020-10-26 | 0.0 |
| 2020-12-25 | 0.0 | 2020-10-23 | 0.0 |
| 2020-12-24 | 0.0 | 2020-10-22 | 0.0 |
| 2020-12-23 | 0.0 | 2020-10-21 | 0.0 |
| 2020-12-22 | 0.0 | 2020-10-20 | 0.0 |
| 2020-12-21 | 0.0 | 2020-10-19 | 0.0 |
| 2020-12-18 | 0.0 | 2020-10-16 | 0.0 |
| 2020-12-17 | 0.0 | 2020-10-15 | 0.0 |
| 2020-12-16 | 0.0 | 2020-10-14 | 0.0 |
| 2020-12-15 | 0.0 | 2020-10-13 | 0.0 |
| 2020-12-14 | 0.0 | 2020-10-12 | 0.0 |
| 2020-12-11 | 0.0 | 2020-10-09 | 0.0 |
| 2020-12-10 | 0.0 | 2020-10-08 | 0.0 |
| 2020-12-09 | 0.0 | 2020-10-07 | 0.0 |
| 2020-12-08 | 0.0 | 2020-10-06 | 0.0 |
| 2020-12-07 | 0.0 | 2020-10-05 | 0.0 |
| 2020-12-04 | 0.0 | 2020-10-02 | 0.0 |
| 2020-12-03 | 0.0 | 2020-10-01 | 0.0 |
| 2020-12-02 | 0.0 | 2020-09-30 | 0.0 |
| 2020-12-01 | 0.0 | 2020-09-29 | 0.0 |
| 2020-11-30 | 0.0 | 2020-09-28 | 0.0 |
| 2020-11-27 | 0.0 | 2020-09-25 | 0.0 |
| 2020-11-26 | 0.0 | 2020-09-24 | 0.0 |
| 2020-11-25 | 0.0 | 2020-09-23 | 0.0 |
Agenus PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Compare
NAS:BSTC
NAS:CTMX
NAS:SYRS
NAS:FULC
NAS:XBIT
NAS:MIRM
NAS:RAPT
NAS:PGEN
NAS:MRUS
NAS:CALA
OCSE:NOVO B
ASX:CSL
NAS:VRTX
NAS:REGN
XKRX:207940
NAS:SGEN
NAS:MRNA
NAS:ALXN
XKRX:068270
NAS:INCY
Address
3 Forbes Road, Lexington, MA, USA, 02421-7305
Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharpe & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others.